La Commission européenne autorise TECVAYLI®▼ (teclistamab) de Johnson & Johnson associé au daratumumab dans le traitement du myélome multiple récidivant ou réfractaire, offrant ainsi une nouvelle référence thérapeutique potentielle
RegulatoryapprovedTECVAYLIdaratumumabPositive
AI Analysis
Summary
The European Commission approved an expanded indication for Johnson & Johnson's TECVAYLI (teclistamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma as a second-line therapy option.
Outcome Details
European Commission approved expanded indication for TECVAYLI in combination with daratumumab for relapsed or refractory multiple myeloma as second-line treatment
Importance:8/10
Sentiment:
0.85
European Commission approvalLabel expansionMultiple myelomaCombination therapySecond-line treatment
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 24, 2026 11:08 AM